Novo argues that Eli Lilly’s advertisements for its GLP-1 drugs are “deliberately simple and deliberately false,” causing harm to both Novo and “the patients Lilly deceives.”
Read More
The deal comes about three months after President Donald Trump signed an executive order directing the U.S. Food and Drug Administration and other federal agencies to speed research and loosen restrictions on psychedelic drug treatments for mental health conditions.
Read More
In the complaint, Tampa General Hospital calls Eli Lilly and Co.’s move “unconscionable and immoral.”
The appellate court held that Teva plausibly alleged that Lilly breached the two companies’ 2018 settlement agreement, which stipulated that Lilly would not interfere with Teva getting approval for a generic version of Lilly’s osteoporosis drug, Forteo.
Stat reported that Lilly and the FDA allowed a 79-year-old man to gain access to the retatrutide through the FDA’s compassionate use program.
The drugmaker is restricting access to a drug discount program intended for safety-net hospitals in a move the company says is needed to identify waste, fraud and abuse.
The Medicare GLP-1 Bridge program is designed to provide temporary access to GLP-1 obesity drugs while federal officials examine longer-term approaches to obesity treatment through Medicare.
A race is shaping up among drug manufacturers that are vying to roll out better options when it comes to weight-loss drugs.
At the American Diabetes Association meeting in New Orleans, market leader Eli Lilly and Co. asserted its dominance in the weight-loss market.
After transforming the treatment of diabetes and weight loss, a growing body of research is raising the possibility that these drugs may help protect against cancer.
Trial patients who received the drug after surgery or radiation therapy experienced an 83% reduction in the risk of disease recurrence or death compared with those who received a placebo.
Eli Lilly and Co. this month unveiled startling new data for an experimental weight-loss drug. The breakthrough also is prompting some doctors to urge caution.
CVS Caremark will add Foundayo coverage on June 1 and resume covering Zepbound on Oct. 1.
The Indianapolis-based drugmaker said some trial participants saw a level of weight loss similar to what patients experience after bariatric surgery.
The Indianapolis drugmaker is purchasing Curevo Inc., LimmaTech Biologics AG and Vaccine Co. Inc. to expand its research and development efforts in infectious disease.
Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff.
The case against Lilly centered on the rebates that drug companies must pay to state Medicaid programs to subsidize some of the cost.
The Indianapolis-based drugmaker will work to support UNICEF’s efforts to strengthen primary health care systems to prevent, detect and manage noncommunicable diseases in children and adolescents.
The Indianapolis-based drugmaker is marking 150 years since Col. Eli Lilly founded his company on May 10, 1876.
Former Indianapolis Colts quarterback Peyton Manning emceed the event, which took place before about 500 attendees at the new Lilly Event Center in downtown Indianapolis.
The move comes as Lilly has embarked on a spree of large acquisitions, including two of its most-expensive transactions ever.
Lilly’s latest commitment at the LEAP District brings the company’s total investment there since 2022 to $18 billion.
